<DOC>
	<DOC>NCT00853086</DOC>
	<brief_summary>This study is conducted in Europe. The purpose of this retrospective study is to collect additional safety information of patients with haemophilia and inhibitors who are treated with rFVIIa.</brief_summary>
	<brief_title>Post-marketing Safety Surveillance of NovoSevenÂ® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database</brief_title>
	<detailed_description>Non-interventional, retrospective data collection on standard treatments of haemophilia A and B patients with inhibitors in the UK.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>All haemophilia A or B patients with inhibitors treated with NovoSeven are included No exclusion criteria beyond the contraindications described in the approved product information text</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>